EUVIMEDEUVIMED entdecken
Crossref

Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy

Shuang Gao, Xueqiao Yu, Yang Li, Lingling Tao, Saihan Bao, Siliang Zhang, Liqiu Ma

Anticancer Research · 2026

DOI: 10.21873/anticanres.18007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Shuang Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P.R. China. Hauptthemen laut MEDLINE: Breast Neoplasms, Mastectomy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Lymphovascular invasion (LVI) is a strong prognostic factor associated with poor survival outcomes in breast cancer. However, the clinical benefit of postmastectomy radiotherapy (PMRT) for early-stage disease remains uncertain. This study aimed to evaluate PMRT efficacy and related prognostic factors in real-world settings. PATIENTS AND METHODS: We retrospectively analyzed 322 postoperative breast cancer patients with pathologically confirmed LVI who received radiotherapy (RT) between October 2017 and July 2020. Patients were categorized into two groups: Group A (pT1-2N1M0, n=273), who underwent modified radical mastectomy (MRM) with or without adjuvant RT; and Group B [stage II, ypN0 after neoadjuvant chemotherapy (NAC) and surgery, with or without adjuvant RT, n=49]. Intergroup differences were assessed using the chi-squared test, and Kaplan-Meier analysis estimated local recurrence-free survival (LRFS), disease-free survival (DFS), overall survival (OS), and distant DFS (DDFS). RESULTS: Group A: Patients who received adjuvant RT had significantly improved 5-year LRFS (94.4% vs. 85.5%, HR=0.359, 95% CI=0.147-0.879; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMastectomyHumansFemaleRadiotherapy, AdjuvantRetrospective StudiesMiddle AgedNeoplasm StagingLymphatic MetastasisAdultPrognosisNeoplasm InvasivenessAgedDisease-Free SurvivalNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Breast cancerclinical decision-makinglymphovascular invasionprognosisradiotherapy

Autor:innen und Institutionen

  • Department of Breast Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P.R. China.
  • Department of Breast Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P.R. China; zhangsl@hrbmu.edu.cn.
  • Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan zhangsl@hrbmu.edu.cn.

Zitieren

APA

Gao, S., Yu, X., Li, Y., Tao, L., Bao, S., Zhang, S., & Ma, L. (2026). Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy. Anticancer Research. https://doi.org/10.21873/anticanres.18007

Vancouver

Gao S, Yu X, Li Y, Tao L, Bao S, Zhang S, et al. Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy. Anticancer Research. 2026. doi:10.21873/anticanres.18007

BibTeX
@article{Gao2026,
  author = {Gao, Shuang and Yu, Xueqiao and Li, Yang and Tao, Lingling and Bao, Saihan and Zhang, Siliang and Ma, Liqiu},
  title = {Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18007}
}
Kostenlos starten →